

**DRUG PRIOR AUTHORIZATION COMMITTEE MEETING**  
**June 21, 2018**  
**Department of Natural Resources, 1101 Riverside Drive,**  
**Lacharette/Nightingale Rooms,**  
**Jefferson City, MO**

**Committee Members Present**

Conrad Balcer, D.O., Chair  
Jennifer Kemp-Oestreich, Pharm D  
Laine Young-Walker, MD  
Morgan Sperry, Pharm D \*Non-voting member this meeting\*  
Pat Bryant, Pharm D

**Guest of Committee Member**

Patrick Dudenhoeffer

**Contractors in Attendance:**

Joshua Moore, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Janelle Sheen, Pharm D, Conduent  
Rick Pope, Pharm D, Magellan  
Geri Roling, Wipro  
Chelsea Pendleton, Wipro

**Others Attending:**

Michael Lafond, Abbvie  
Ashley Polce, Abbvie  
Michael Boskello, Alkermes  
Evan Rushing, Alkermes  
Randy McGinley, Bayer  
Robert Kyle, Biogen

Aaron Shaw, BIPi  
Chi Kohuhoff, Braeburn  
Lisa Tootle, Bristol-Myer Squibb  
Gia McLean, Celgene  
Tamara Kenny, CCSTL  
Evelyn Gittinger, DZ

**MO HealthNet Staff Present:**

Jennifer Tidball, Acting Director  
Caitlin Whaley, Legislative Director DSS  
Mark Roaseau, R.Ph, Clinical Pharmacist  
Sharie Hahn, Special Council  
Elizabeth Sissom, RN, Clinical Management  
Angela Wilson, Pharmacy Operations Manager  
Frances (Franki) Moseley, Administrative Office Support Assistant  
Mitch Ruth, Pharmacy Fiscal Unit Manager  
Dr. Timothy Kling, MD, Assistant Medical Director  
Lisa E. Smith, Program Development Specialist  
Dr. Samar Muzaffar, MD MPH, Chief Medical Officer

Tami Sova, Biogen  
 Heather Clark, IntersectENT  
 Scott Poole, IntersectENT  
 Jennifer Stoffel, Janssen  
 Mary Jo, DeFlorio, Johnson & Johnson  
 Brittany Mobley, KOMU  
 Tom Graysen, Lilly  
 Kate Holly, LSEM  
 Rebecca McDonald, LSEM  
 Mark Herlent, Lundbeck  
 Meghan Kerrigan, Merck  
 Patrick Dudenhoefter, MPA  
 Dr. Sherifa Iqbal, MPPA  
 Kim Mure, MPA  
 Ed Bothe, NAMI  
 Jacqueline Hudson, NAMI  
 Alan Stoutz, NAMI  
 Gena Terlizzi, NAMI  
 Shawn Wilson, NAMI

Sheila Suva, Erscei  
 Matt Bradley, Novartis  
 Lon Lowery, Novartis  
 Jason Lurk, Novo Nordisk  
 Marla Wiedenmann, Novo Nordisk  
 Tom Rudd, NVS  
 Rick Kegler, Otsuka  
 Terry McCurren, Otsuka  
 Cheryl Reid, Otsuka  
 Amy Linss, PFH/CFM  
 Jim Bauman, Pfizer  
 Rachael Berry, Pfizer  
 Rob Hanson, Pfizer  
 Phillip King, Pfizer  
 Joel L. Young, Rhodex  
 Chris VanWynen, Sarepta  
 Tyrone McBayne, Shire  
 Ron Shnare, Shire  
 Trey Cardex, Silvergate

Kathi Harness  
 Scott Hockina, Spark TX  
 Rei Nakamara, Spark TX  
 Mary Kelley, Sunovion  
 Mark Wampler, Sunovion  
 Ingrid Ma, Sunovion  
 Jennifer Wilbanks, Sunovion  
 Robert Pearce, TEVA  
 Justin Barnes, Tris Pharma  
 Anthony Locke, Tris Pharma  
 Rob Low, UCB  
 Katrina Paumier, UCB  
 Aimee Redhair, UCB  
 Eric Gardner, Vertex  
 Karla Kenyon, Vertex  
 Casey Johnson, Viiv  
 Christy Heine, Viking HCS  
 Gregg Sansbury, West-Ward

|   |   |
|---|---|
| <b>Welcome, Introductions and Opening Remarks</b> | Conrad Balcer, Chair, called the meeting to order. Mark Roaseau introduced himself and started the introductions and opening remarks. Jennifer Kemp-Oestreich introduced a guest, Patrick Dudenhoefter, Pharm D Candidate from St. Louis College of Pharmacy. Sharie Hahn, Special Council, had an Amendment to the Agenda, on the Antipsychotics-2 <sup>nd</sup> Generation PDL, this will be tabled and any comments will not be addressed at this time. Comments are welcome and they will take them into consideration when they do address all of the comments received. |
| <b>Minutes Approval</b>                           | Minutes of the March 2018 Drug PA meeting were reviewed and approved. Laine Young-Walker motioned and Pat Bryant seconded the motion. (See Roll Call Vote)  |
| <b>Pharmacy Program/Budget Update</b>             | Mitch Ruth presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.   |
| <b>Old Business</b>                               |   |

|   |   |
|---|---|
| <b>Old Business Implementation Schedule</b> | An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included March/April, 2018 PDL decisions to be implemented July 2018. Pending ratification, PDL decisions from the June 2018 Drug PA Committee meeting will be implemented October 2018. Schedules may be found on the MHD web page at <a href="https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf">https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf</a>  |
| <b>Late Introduction</b>                    | Conrad Balcer introduced Jennifer Tidball, Acting Director and Caitlin Whaley, Legislative Director DSS to the meeting.   |
| <b>New Business</b>                         |   |
| <b>New Drug Review</b>                      | <p>Mark Roaseau reviewed the new drug products identified for the quarter January, February, March, 2018 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> <li>• <b>Discussion</b> – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending.</li> <li>• <b>Public Hearing</b> – Scott Poole, IntersectENT, commented on Sinuva. Jennifer Wilbanks, Sunovion commented on Lonhala®Magnair.</li> <li>• <b>Decision</b> – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)</li> </ul> |
| <b>Clinical Edits</b>                       |   |
| <b>Luxturna Clinical Edit</b>               | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document.</li> <li>• <b>Public Hearing</b> – Rei Nakamura, Spark TX, commented on Luxturna.</li> <li>• <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Mepsevii Clinical Edit</b>               | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>   |
| <b>Symdeko Clinical Edit</b>                | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>   |
| <b>Yescarta Clinical Edit</b>               | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>   |

| Preferred Drug List (PDL)                            |  |
|--|--|
| <b>Amylin Analogs</b>                                | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>                       |
| <b>Antihyperuricemic Agents</b>                      | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No Comments Entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>      |
| <b>Bile Salts Agents</b>                             | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>                            |
| <b>Bone Deossification Suppression Agents</b>        | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>      |
| <b>BPH Agents</b>                                    | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>      |
| <b>Cephalosporins and Related Antibiotics - Oral</b> | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>      |
| <b>Cryopyrin-Associated Periodic Syndrome (CAPS)</b> | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>                            |
| <b>DPP-IV (Dipeptidyl Peptidase-4) Inhibitors</b>    | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>                            |
| <b>Electrolyte Depleters</b>                         | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul> |
| <b>Fluoroquinolones – Oral</b>                       | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>       |

|   |   |
|---|---|
| <b>GI Antibiotics – Oral:</b>                           | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents</li> <li>• <b>Public Hearing</b> – Megan Kerrigan, Merck commented on Dificide.</li> <li>• <b>Decision</b> – The Committee voted to make a change on the Dificide trial criteria before becoming a preferred drug.. (See Roll Call Vote)</li> </ul>   |
| <b>GLP-1 Receptor Agonists (Anti-Diabetic Mimetics)</b> | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – Jason Lurk, Novo Nordisk commented on Norditropin.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>   |
| <b>Growth Hormones and Growth Factors</b>               | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Roaseau reviewed the criteria document, reviewing preferred and non</li> <li>• <b>Public Hearing</b> – No Comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Hematopoietic Agents</b>                             | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Hepatitis C Therapy</b>                              | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – Michele Puyear, Gilead commented on Eplclusa.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Insulins</b>   | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Insulins – Long Acting</b>                           | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – Jason Lurk, Novo Nordisk commented on Tresiba FlexTouch..</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Insulins – Mix</b>                                   | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Insulins – Rapid Acting</b>                          | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Intravaginal Antibiotics</b>                         | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee made a motion to approve the change of Clindamycin Vaginal Cream to be a preferred agent. Conrad Balcer also commented that the reference materials need to be updated on the PDL's. (See Roll Call Vote)</li> </ul> |

|  |   |
|--|---|
| <b>Macrolides – Adult</b>                                | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>                              |
| <b>Macrolides – Pediatric</b>                            | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>                              |
| <b>Methotrexate Products – Oral and Injectable</b>       | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – Trey Gardoner, Silvergate commented on Xatemp.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>         |
| <b>Multiple Sclerosis (MS) Agents</b>                    | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – Tami Sova, Biogen commented on Tecfidera &amp; Tysabri.</li> <li>• <b>Decision</b> – The Committee voted to approve a change in the criteria. (See Roll Call Vote)</li> </ul> |
| <b>Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors</b> | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Oral Anti-Diabetics: Biguanides</b>                   | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Oral Anti-Diabetics: Combinations</b>                 | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>                              |
| <b>Oral Anti-Diabetics: Meglitinides</b>                 | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Oral Anti-Diabetics: Sulfonylureas 2nd Gen</b>        | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Oral Anti-Diabetics: Thiazolidinediones</b>           | <ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |

|   |   |
|---|---|
| <b>Penicillins</b>                                | <ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Sodium-Glucose Co-Transporter 2 (SGLT2)</b>    | <ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Targeted Immune Modulators</b>                 | <ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – Phillip King, Pfizer commented on Xeljanz. Robert Low, UCB commented on Cimzia. Gia McClean, Celgene commented on Otezla. Donna Osterlund, Genesis commented on Kevzara and how it was not on the Non-Preferred listing like it always was before.</li> <li>● <b>Decision</b> – The Committee made a motion to approve changes in this PDL. (See Roll Call Vote)</li> </ul> |
| <b>Tetracyclines</b>                              | <ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Urinary Tract Antispasmodics</b>               | <ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>  |
| <b>Antipsychotics - 2nd Generation (Atypical)</b> | <ul style="list-style-type: none"> <li>● <b>Discussion</b> – This PDL was tabled until further notice.</li> <li>● <b>Public Hearing</b> – General comments were made by the following list:<br/> Matt Carlisle, Genoa<br/> Connie Fisher, Advocate<br/> Rebecca McDonald, Legal Services<br/> Jacqueline Hudson, NAMI<br/> Gena Terlizzi, NAMI<br/> Ed Bothe, Advocate<br/> Steven from CPS(staff member), Advocate<br/> Alan Stoutz, Advocate<br/> Lon Lowry, Novartis<br/> Ingrid Ma, Sunovion</li> </ul>   |
| <b>ADHD Therapy</b>                               | <ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – Justin Barnes, Tris Pharma commented on Dyanavel XR. Gregg Friedman, Neo Therapeutics commented on Adzenys XR and Cotempla XR-ODT. Dr. Joes Young, Rhodes Pharmaceuticals commented on Aptensio XR. Gina Terlizzi, NAMI commented on the ADHD drug class.</li> <li>● <b>Decision</b> – The Committee moved to table this drug class until further consideration. (See Roll Call Vote)</li> </ul>  |

|   |   |
|---|---|
| <b>Preferred Drug List Announcement</b> | A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: <a href="http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf">http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</a> |
|---|---|

|   |   |
|---|---|
| <b>Conduent Update</b>                              | Conduent did not present the following items for review. These items were included in the packet for the meeting. Here is the list: <ul style="list-style-type: none"> <li>• Call Center Statistics, Claims, Spend, and Diagnosis information for the SSRI's and SNRI's.</li> <li>• New Drug Summary.</li> </ul>  |
| <b>Program Utilization: Top 25 Drugs Summary</b>    | The Top 25 Drugs Summary Reports for the 1st, 2 <sup>nd</sup> , 3 <sup>rd</sup> , & 4th quarter 2017 were provided in the packets for review. Two versions were provided: one report ranked drug spend by dollars and the other by utilization/claims.  |
| <b>Call Center Statistics/ Cyber Access Reports</b> | In the packets provided for the meeting were the following handouts and reports: <ul style="list-style-type: none"> <li>• A handout detailing pharmacy help desk call center activity</li> <li>• Cyber Access Active User Counts and Logging Information.</li> <li>• Reports were also provided detailing the number and type of prescribers and active users on Cyber Access.</li> </ul>   |
| <b>Adjourn</b>                                      | The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call) The next meeting of the <b>Drug Prior Authorization Committee</b> is scheduled for <b>September 20, 2018 at the Missouri Coalition for Community Behavioral Healthcare Building, Lower Level CEO Room, 221 Metro Drive, Jefferson City, MO.</b> |



**Roll Call Votes June 21, 2018**

| <b><u>Roll Call<br/>FOR June<br/>21, 2018</u></b> |                |   |                 |                 |                |                 |                          |
|---|----------------|---|-----------------|-----------------|----------------|-----------------|--------------------------|
| <b><u>Member</u></b>                              | <b>Minutes</b> | <b>New<br/>Drugs/Product<br/>Review</b> | <b>Luxturna</b> | <b>Mepsivii</b> | <b>Symdeko</b> | <b>Yescarta</b> | <b>Amylin<br/>Analog</b> |
| <b>Conrad Balcer,<br/>D.O.</b>                    | Y              | Y                                       | Y               | Y               | Y              | Y               | Y                        |
| <b>Pat Bryant,<br/>Pharm D</b>                    | S,Y            | S,Y                                     | Y               | S,Y             | Y              | M,Y             | Y                        |
| <b>Laine Young-<br/>Walker, M.D.</b>              | M,Y            | Y                                       | S,Y             | M,Y             | M,Y            | S,Y             | M,Y                      |
| <b>Morgan Sperry,<br/>Pharm D-<br/>Alternate</b>  | AL             | AL                                      | AL              | AL              | AL             | AL              | AL                       |
| <b>Jennifer Kemp-<br/>Ostreich,<br/>Pharm D</b>   | Y              | M,Y                                     | M,Y             | Y               | S,Y            | Y               | S,Y                      |
| <b>Laura Kingsley,<br/>Pharm D</b>                | A              | A                                       | A               | A               | A              | A               | A                        |

| <u>Member</u>                    | Antihyperuricemic Agents | Bile Salts Agents | Bone Deossification Suppression Agents | BPH Agents | Cephalosporins and Related Antibiotics | Cryopyrin-Associated Periodic Syndrome | Dpp-IV Inhibitors |
|----------------------------------|--------------------------|-------------------|--|------------|--|--|-------------------|
| Conrad Balcer, D.O.              | Y                        | Y                 | Y                                      | Y          | Y                                      | Y                                      | Y                 |
| Pat Bryant, Pharm D              | Y                        | S,Y               | S,Y                                    | M,Y        | S,Y                                    | S,Y                                    | S,Y               |
| Laine Young-Walker, M.D.         | S,Y                      | Y                 | Y                                      | S,Y        | M,Y                                    | M,Y                                    | Y                 |
| Morgan Sperry, Pharm D-Alternate | AL                       | AL                | AL                                     | AL         | AL                                     | AL                                     | AL                |
| Jennifer Kemp-Ostreich, Pharm D  | M,Y                      | M,Y               | M,Y                                    | Y          | Y                                      | Y                                      | M,Y               |
| Laura Kingsley, Pharm D          | A                        | A                 | A                                      | A          | A                                      | A                                      | A                 |

| <b><u>Member</u></b>                    | <b>Electrolyte Depleters</b> | <b>Fluoroquinolones - Oral</b> | <b>GI Antibiotics - Oral</b> | <b>GLP - 1 Receptor Agonists</b> | <b>Growth Hormones and Growth Factors</b> | <b>Hematopoietic Agents</b> | <b>Hepatitis C Therapy</b> |
|---|------------------------------|--------------------------------|------------------------------|----------------------------------|---|-----------------------------|----------------------------|
| <b>Conrad Balcer, D.O.</b>              | Y                            | Y                              | Y                            | Y                                | Y   | Y                           | Y                          |
| <b>Pat Bryant, Pharm D</b>              | M,Y                          | S,Y                            | S,Y                          | Y                                | S,Y                                       | M,Y                         | Y                          |
| <b>Laine Young-Walker, M.D.</b>         | S,Y                          | M,Y                            | Y                            | S,Y                              | M,Y                                       | S,Y                         | M,Y                        |
| <b>Morgan Sperry, Pharm D-Alternate</b> | AL                           | AL                             | AL                           | AL                               | AL  | AL                          | AL                         |
| <b>Jennifer Kemp-Ostreich, Pharm D</b>  | Y                            | Y                              | M,Y                          | M,Y                              | Y   | Y                           | S,Y                        |
| <b>Laura Kingsley, Pharm D</b>          | A                            | A                              | A                            | A                                | A   | A                           | A                          |

| <u>Member</u>                           | Insulins | insulins-LA | Insulins-Mix | Insulins-RA | Intravaginal Antibiotics | Macrolides-Adult | Macrolides-Pediatric |
|---|----------|-------------|--------------|-------------|--------------------------|------------------|----------------------|
| <b>Conrad Balcer, D.O.</b>              | Y        | Y           | Y            | Y           | Y                        | Y                | Y                    |
| <b>Pat Bryant, Pharm D</b>              | M,Y      | Y           | M,Y          | S,Y         | M,Y                      | M,Y              | S,Y                  |
| <b>Laine Young-Walker, M.D.</b>         | S,Y      | S,Y         | S,Y          | M,Y         | Y                        | S,Y              | M,Y                  |
| <b>Morgan Sperry, Pharm D-Alternate</b> | AL       | AL          | AL           | AL          | AL                       | AL               | AL                   |
| <b>Jennifer Kemp-Ostreich, Pharm D</b>  | Y        | M,Y         | Y            | Y           | S,Y                      | Y                | Y                    |
| <b>Laura Kingsley, Pharm D</b>          | A        | A           | A            | A           | A                        | A                | A                    |

| <b>Member</b>                           | <b>Methotrexate Products-Oral and Injectable</b> | <b>Multiple Sclerosis (MS)</b> | <b>Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors</b> | <b>Oral Anti-Dibetics: Biguanides</b> | <b>Oral Anti-Diabetics: Conbinations</b> | <b>Oral Anti Diabetics: Meglitinides</b> | <b>Oral Anti Diabetics: Sulfonylureas 2nd Generation</b> |
|---|--|--------------------------------|--|---------------------------------------|--|--|--|
| <b>Conrad Balcer, D.O.</b>              | Y  | Y                              | Y  | Y                                     | Y  | Y  | Y  |
| <b>Pat Bryant, Pharm D</b>              | Y  | M,Y                            | S,Y  | M,Y                                   | Y  | M,Y                                      | S,Y  |
| <b>Laine Young-Walker, M.D.</b>         | M,Y  | S,Y                            | Y  | S,Y                                   | S,Y                                      | S,Y                                      | Y  |
| <b>Morgan Sperry, Pharm D-Alternate</b> | AL   | AL                             | AL   | AL                                    | AL                                       | AL                                       | AL   |
| <b>Jennifer Kemp-Ostreich, Pharm D</b>  | S,Y  | Y                              | M,Y  | Y                                     | M,Y                                      | Y  | M,Y  |
| <b>Laura Kingsley, Pharm D</b>          | A  | A                              | A  | A                                     | A  | A  | A  |

| <b>Member</b>                                    | <b>Oral Ant-Diabetics:<br/>Thiazolidinediones</b> | <b>Penicilins</b> | <b>SGLT2<br/>Inhibitors</b> | <b>Targeted<br/>Immune<br/>Modulators</b> | <b>Tetracyclines</b> | <b>Urinary Tract<br/>Antispasmodics</b> | <b>Antipsychotics</b> |
|--|---|-------------------|-----------------------------|---|----------------------|---|-----------------------|
| <b>Conrad Balcer,<br/>D.O.</b>                   | Y   | Y                 | Y                           | Y   | Y                    | Y                                       | Y                     |
| <b>Pat Bryant,<br/>Pharm D</b>                   | M,Y   | S,Y               | M,Y                         | Y   | S,Y                  | Y                                       | Y                     |
| <b>Laine Young-<br/>Walker, M.D.</b>             | Y   | Y                 | S,Y                         | S,Y                                       | M,Y                  | M,Y                                     | Y                     |
| <b>Morgan Sperry,<br/>Pharm D-<br/>Alternate</b> | AL  | AL                | AL                          | AL  | AL                   | AL                                      | AL                    |
| <b>Jennifer Kemp-<br/>Ostreich,<br/>Pharm D</b>  | S,Y   | M,Y               | Y                           | M,Y                                       | Y                    | S,Y                                     | Y                     |
| <b>Laura Kingsley,<br/>Pharm D</b>               | A   | A                 | A                           | A   | A                    | A                                       | A                     |

| <u>Member</u>                    | ADHD | Motion to Close | Meeting Adjourned |    |    |    |   |
|----------------------------------|------|-----------------|-------------------|----|----|----|---|
| Conrad Balcer, D.O.              | Y    | Y               | Y                 |    |    |    |   |
| Pat Bryant, Pharm D              | Y    | Y               | S,Y               |    |    |    |   |
| Laine Young-Walker, M.D.         | M,Y  | M,Y             | M,Y               |    |    |    |   |
| Morgan Sperry, Pharm D-Alternate | AL   | AL              | AL                | AL | AL | AL | A |
| Jennifer Kemp-Ostreich, Pharm D  | S,Y  | S,Y             | Y                 |    |    |    |   |
| Laura Kingsley, Pharm D          | A    | A               | A                 | A  | A  | A  | A |

**Roll Call Abbreviations:**

**A-Absent**

**AL-Alternate**

**R-Ratify**

**M-Motion**

**S-Second**

**Y-Yes to the vote**